HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (1- (4- hydroxyphenyl)- 2- phenylbuten- 1- yl)phenoxy- n- butyric acid

structure in first source

Also Known As:

4-HBA; 4HBA cpd

Networked: 24 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Butyrates: 2613
      - 4-(1-(4-hydroxyphenyl)-2-phenylbuten-1-yl)phenoxy-n-butyric acid: 24
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Butyrates: 2613
      - 4-(1-(4-hydroxyphenyl)-2-phenylbuten-1-yl)phenoxy-n-butyric acid: 24

Experts

1.	Zhao, Jing: 3 articles (07/2013 - 01/2010)
2.	Zhao, Yong: 3 articles (07/2013 - 01/2010)
3.	Kim, Il-Doo: 2 articles (04/2018 - 01/2017)
4.	Kim, Seung-Woo: 2 articles (04/2018 - 01/2017)
5.	Lee, Hahnbie: 2 articles (04/2018 - 01/2017)
6.	Lee, Hye-Kyung: 2 articles (04/2018 - 01/2017)
7.	Lee, Ja-Kyeong: 2 articles (04/2018 - 01/2017)
8.	Luo, Lidan: 2 articles (04/2018 - 01/2017)
9.	Yu, Shan-Shan: 2 articles (02/2011 - 01/2010)
10.	Liu, Ke Jian: 2 articles (03/2003 - 05/2002)

Related Diseases

1.	Cerebral Infarction 02/01/2011 - "Pre-treatment with 4-HBA (50,100 mg/kg) significantly reduced the cerebral infarct size and improved the neurological symptoms. " 07/01/2013 - "Furthermore, 4-HBA reduced the cerebral infarct size and improved the behavioral parameters after cerebral ischemia. "
2.	Ischemia 01/13/2010 - "Neurological evaluation and Nissl-staining of the 4-HBA group were improved significantly compared to the untreated ischemia group. " 01/13/2010 - "Under the treatment of 50 mg/kg 4-HBA, total (100.76+/-2.90 mm(3)), cortical (64.91+/-1.46 mm(3)), and sub-cortical (38.77+/-2.78 mm(3)) infarct volumes were significantly decreased in comparison to ischemia-reperfusion values. " 11/21/2007 - "Treatment with 4-HBA did not affect NR1 expression levels, down-regulated 8-OHdG immunoreactivity, and increased GABA-T expression levels after global ischemia, suggesting that 4-HBA inhibited NR1 stimulation. " 03/15/2003 - "After microdialysis probe delivery of 4-HBA, (*)OH production was significantly increased in the striatal core during both ischemia and reperfusion. "
3.	Brain Ischemia (Cerebral Ischemia) 05/01/2002 - "Because of interrupted blood flow during cerebral ischemia and reperfusion, delivery of 4-HBA through the microdialysis probe is a preferred method to systemic administration such as intravenous infusion. " 07/01/2013 - "Furthermore, 4-HBA reduced the cerebral infarct size and improved the behavioral parameters after cerebral ischemia. " 01/13/2010 - "These results suggested that 4-HBA ameliorated ischemic injury induced by transient focal cerebral ischemia in rats, and this neuroprotective effect may be partly related to attenuate apoptosis pathway."
4.	Leukemia 01/01/2021 - "Therefore, these current studies could provide useful information about the nature of 4-HBA or VA binding to protein HSA and their anticancer activities in both of these types of leukemia cells. " 01/01/2021 - "In addition, the 4-HBA and VA decreased in cell viability for both doxorubicin-sensitive K562 and doxorubicin-resistant K562/Dox leukemia cells in a dose- and time-dependence manner. " 01/01/2021 - "The effect of 4-HBA and VA on anti-proliferation was also studied on doxorubicin-sensitive K562 and doxorubicin-resistant K562/Dox leukemia cells using resazurin assay. " 01/01/2021 - "The objective was to investigate the interaction of 4-HBA or VA with human serum albumin (HSA) and their anti-proliferation properties on doxorubicin-sensitive K562 and doxorubicin-resistant K562/Dox leukemia cells. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2022 - "Together, our study provides new insights into the role of gut microbiome in exercise protection to MI, offers opportunities to modulate cardiovascular diseases by exercise, microbiome and gut microbiota-derived 3-HPA and 4-HBA. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Scopolamine (Hyoscine)
3.	vanillin
4.	3-hydroxypropionaldehyde
5.	Neuroprotective Agents
6.	Caspase 3 (Caspase-3)
7.	Staphylococcal Protein A (Protein A)
8.	Indicators and Reagents (Reagents)
9.	gamma-Aminobutyric Acid (GABA)
10.	Enzymes

Related Therapies and Procedures

1.	Intravenous Infusions